Baxter's 2025 results reveal supply chain struggles and shifting market demand
Baxter International is set to release its 2025 annual results on February 12, 2026. The medical supplies company has faced a turbulent year, with operational setbacks and shifting market demand affecting its performance.
The company's struggles began in late 2024 when Hurricane Helene disrupted operations at its North Cove plant. This facility produces around 60% of the U.S. supply of IV solutions, leading to lasting supply chain issues. Baxter has since revised its full-year guidance, citing ongoing challenges with both production and its Novum IQ pump portfolio.
In the third quarter of 2025, Baxter reported mixed results. Adjusted earnings per share beat expectations, but revenue came in below forecasts. The firm has also cut roughly 90 jobs at its Marion facility as part of a broader effort to realign capacities. Market demand for infusion therapies has shifted, prompting Baxter to adjust its operations accordingly.
The company's stock reflects these difficulties. While shares have climbed about 11% since January 2026, they remain nearly 38% lower than a year ago. Investment firm FMR LLC currently holds a 6.8% stake in Baxter.
Baxter will provide a full breakdown of its fourth-quarter and annual performance next month. The analyst call will also address plans for 2026, including steps to stabilise the supply chain. The company continues to navigate the aftermath of Hurricane Helene and changing demand for its products.
